Published in Proc Natl Acad Sci U S A on March 15, 2004
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A (2006) 2.43
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2005) 2.00
Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One (2014) 1.96
Malarial proteases and host cell egress: an 'emerging' cascade. Cell Microbiol (2008) 1.86
Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. Nucleic Acids Res (2009) 1.71
A malarial cysteine protease is necessary for Plasmodium sporozoite egress from oocysts. J Exp Med (2005) 1.71
Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci U S A (2004) 1.34
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother (2011) 1.16
Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. PLoS Pathog (2006) 1.15
The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. Proc Natl Acad Sci U S A (2005) 1.14
Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proc Natl Acad Sci U S A (2010) 1.09
Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob Agents Chemother (2006) 1.06
Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J Med Chem (2009) 1.06
Plasmodium falciparum responds to amino acid starvation by entering into a hibernatory state. Proc Natl Acad Sci U S A (2012) 1.05
Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc Natl Acad Sci U S A (2006) 1.02
Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. PLoS One (2009) 1.02
A new model for hemoglobin ingestion and transport by the human malaria parasite Plasmodium falciparum. J Cell Sci (2008) 1.01
Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother (2009) 0.98
The cathepsin L of Toxoplasma gondii (TgCPL) and its endogenous macromolecular inhibitor, toxostatin. Mol Biochem Parasitol (2008) 0.98
Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc Natl Acad Sci U S A (2016) 0.96
New roles for perforins and proteases in apicomplexan egress. Cell Microbiol (2009) 0.96
Cathepsin proteases in Toxoplasma gondii. Adv Exp Med Biol (2011) 0.96
Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. Biochem J (2006) 0.94
Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl Trop Dis (2011) 0.93
Eimeripain, a cathepsin B-like cysteine protease, expressed throughout sporulation of the apicomplexan parasite Eimeria tenella. PLoS One (2012) 0.92
Regulatory elements within the prodomain of Falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparum. PLoS One (2009) 0.91
Proteases as regulators of pathogenesis: examples from the Apicomplexa. Biochim Biophys Acta (2011) 0.90
BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. Mol Biochem Parasitol (2007) 0.89
Biochemical properties of a novel cysteine protease of Plasmodium vivax, vivapain-4. PLoS Negl Trop Dis (2010) 0.86
Improved prediction of malaria degradomes by supervised learning with SVM and profile kernel. Genetica (2008) 0.85
Falcipain-1, a Plasmodium falciparum cysteine protease with vaccine potential. Infect Immun (2007) 0.84
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d. Antimicrob Agents Chemother (2006) 0.84
Structure-function of falcipains: malarial cysteine proteases. J Trop Med (2012) 0.84
Blocking Plasmodium falciparum development via dual inhibition of hemoglobin degradation and the ubiquitin proteasome system by MG132. PLoS One (2013) 0.84
The antimalarial natural product symplostatin 4 is a nanomolar inhibitor of the food vacuole falcipains. Chem Biol (2012) 0.83
In vitro and in vivo silencing of plasmodial dhs and eIf-5a genes in a putative, non-canonical RNAi-related pathway. BMC Microbiol (2012) 0.83
Distinct and stage specific nuclear factors regulate the expression of falcipains, Plasmodium falciparum cysteine proteases. BMC Mol Biol (2008) 0.83
Characterization of the autophagy marker protein Atg8 reveals atypical features of autophagy in Plasmodium falciparum. PLoS One (2014) 0.82
Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure. Emerg Infect Dis (2015) 0.82
Plasmodium yoelii inhibitor of cysteine proteases is exported to exomembrane structures and interacts with yoelipain-2 during asexual blood-stage development. Cell Microbiol (2013) 0.81
The Ionic and hydrophobic interactions are required for the auto activation of cysteine proteases of Plasmodium falciparum. PLoS One (2012) 0.80
Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J Cell Sci (2015) 0.80
Imidazoquines as antimalarial and antipneumocystis agents. J Med Chem (2009) 0.80
Proteases in malaria parasites - a phylogenomic perspective. Curr Genomics (2011) 0.79
Antimalarial activity of thiosemicarbazones and purine derived nitriles. Bioorg Med Chem Lett (2009) 0.79
Inhibitor of cysteine proteases is critical for motility and infectivity of Plasmodium sporozoites. MBio (2013) 0.79
Centenary celebrations article: Cysteine proteases of human malaria parasites. J Parasit Dis (2011) 0.78
Purification of components of the translation elongation factor complex of Plasmodium falciparum by tandem affinity purification. Eukaryot Cell (2007) 0.78
Intracellular proteolysis of kininogen by malaria parasites promotes release of active kinins. Malar J (2012) 0.78
Expression, characterization, and cellular localization of knowpains, papain-like cysteine proteases of the Plasmodium knowlesi malaria parasite. PLoS One (2012) 0.78
Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets. Front Pharmacol (2016) 0.76
Enone- and chalcone-chloroquinoline hybrid analogues: in silico guided design, synthesis, antiplasmodial activity, in vitro metabolism, and mechanistic studies. J Med Chem (2011) 0.75
Identification of Chalcones as Fasciola hepatica Cathepsin L Inhibitors Using a Comprehensive Experimental and Computational Approach. PLoS Negl Trop Dis (2016) 0.75
The Genome of Nosema sp. Isolate YNPr: A Comparative Analysis of Genome Evolution within the Nosema/Vairimorpha Clade. PLoS One (2016) 0.75
Chemical biology approaches for the study of apicomplexan parasites. Mol Biochem Parasitol (2013) 0.75
Responsiveness of parasite Cys His proteases to iron redox. Parasitol Res (2006) 0.75
Deletion of the rodent malaria ortholog for falcipain-1 highlights differences between hepatic and blood stage merozoites. PLoS Pathog (2017) 0.75
Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane. J Med Chem (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Human malaria parasites in continuous culture. Science (1976) 59.70
Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol (1979) 23.90
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell (2000) 10.72
The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg (2001) 8.21
Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A (1997) 5.75
Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol (1997) 3.66
A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest (1988) 2.95
Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci U S A (2002) 2.24
A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science (2002) 2.20
Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem (2000) 2.16
Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem J (2001) 2.00
Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J (1994) 2.00
Nutritional requirements of Plasmodium falciparum in culture. I. Exogenously supplied dialyzable components necessary for continuous growth. J Protozool (1985) 1.91
Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest (1991) 1.91
Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood (2003) 1.72
Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr Drug Targets (2000) 1.68
Biological roles of proteases in parasitic protozoa. Annu Rev Biochem (2001) 1.66
Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J Clin Invest (1993) 1.61
Optimisation of flow cytometric measurement of parasitaemia in plasmodium-infected mice. Int J Parasitol (2000) 1.61
Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor). J Protozool (1992) 1.56
Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Mol Biochem Parasitol (1992) 1.51
Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol (1996) 1.47
Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem (1999) 1.43
Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum. Antimicrob Agents Chemother (2001) 1.40
Cysteine proteases of malaria parasites: targets for chemotherapy. Curr Pharm Des (2002) 1.34
Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. Exp Parasitol (1986) 1.29
Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother (1998) 1.27
High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett (1994) 1.23
Proteases of protozoan parasites. Adv Parasitol (1999) 1.22
Transcriptional analysis of genes encoding enzymes of the folate pathway in the human malaria parasite Plasmodium falciparum. Mol Microbiol (2002) 1.16
Expression of green fluorescent protein in Plasmodium falciparum. Mol Biochem Parasitol (1997) 1.10
Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. Mol Biochem Parasitol (2003) 1.01
Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Blood (1996) 0.96
Stage-specific antimalarial activity of cysteine protease inhibitors. Biol Chem (2002) 0.93
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg (2006) 2.43
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg (2007) 2.30
Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis (2008) 2.28
Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother (2007) 2.12
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2005) 2.00
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2003) 1.96
Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2006) 1.95
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis (2011) 1.94
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis (2006) 1.93
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr (2009) 1.83
Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS (2007) 1.79
Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol (2006) 1.78
Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother (2007) 1.75
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J (2011) 1.73
The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar J (2006) 1.73
Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J (2012) 1.65
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg (2006) 1.64
Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg (2003) 1.59
Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg (2005) 1.59
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg (2004) 1.58
Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med (2012) 1.58
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health (2004) 1.56
Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. Am J Trop Med Hyg (2005) 1.53
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem (2004) 1.49
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis (2014) 1.44
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother (2007) 1.44
Use of the slide positivity rate to estimate changes in malaria incidence in a cohort of Ugandan children. Malar J (2009) 1.43
Plasmodium food vacuole plasmepsins are activated by falcipains. J Biol Chem (2008) 1.43
Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. PLoS One (2009) 1.43
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One (2010) 1.42
Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol (2008) 1.39
Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob Agents Chemother (2003) 1.39
The seroprevalence of Helicobacter pylori and its relationship to malaria in Ugandan children. Trans R Soc Trop Med Hyg (2011) 1.39
Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J (2010) 1.34
False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol (2006) 1.34
Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci U S A (2004) 1.34
Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS (2010) 1.32
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg (2005) 1.29
Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One (2010) 1.27
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J (2008) 1.27
Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics (2008) 1.23
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorg Med Chem Lett (2009) 1.22
Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis (2009) 1.22
Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Malar J (2010) 1.21
Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg (2006) 1.20
Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis (2007) 1.19
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg (2004) 1.18
Development of protease inhibitors for protozoan infections. Curr Opin Infect Dis (2008) 1.16
In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother (2011) 1.16
Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. PLoS Pathog (2006) 1.15
The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. Proc Natl Acad Sci U S A (2005) 1.14
Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis (2009) 1.14
Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood (2012) 1.13
Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J Infect Dis (2004) 1.13
Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture. J Infect Dis (2008) 1.12
Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg Med Chem (2005) 1.12
Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol (2005) 1.11
Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis (2006) 1.11
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J (2009) 1.11
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg Med Chem Lett (2005) 1.11
Falcipain cysteine proteases require bipartite motifs for trafficking to the Plasmodium falciparum food vacuole. J Biol Chem (2007) 1.10
Folding of the Plasmodium falciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain. J Biol Chem (2002) 1.09
Malaria in Uganda: challenges to control on the long road to elimination. II. The path forward. Acta Trop (2011) 1.09
Dipeptide vinyl sultams: synthesis via the Wittig-Horner reaction and activity against papain, falcipain-2 and Plasmodium falciparum. Bioorg Med Chem Lett (2006) 1.09
Resistance-mediating polymorphisms in Plasmodium falciparum infections in Kinshasa, Democratic Republic of the Congo. Am J Trop Med Hyg (2009) 1.08
Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2'. Exp Parasitol (2005) 1.07